Please ensure Javascript is enabled for purposes of website accessibility

Can Biotech Dominate for a 4th Year in a Row?

By Brian Orelli, PhD – Feb 2, 2014 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Only if investors continue to accept risk.

Biotech has been on one heck of a terror. According to Credit Suisse, the industry has been the top industry for the past three years, trouncing the S&P 500.

Index

2011

2012

2013

Biotech return

22%

38%

74%

S&P 500 return

0%

13%

30%

For the biotech industry to dominate for a fourth year in a row, one or more of the following things need to happen.

Flight to risk
One of the reasons the biotechnology sector has done so well recently is investors have been willing to take on more risk. As buyers outpace sellers, the value investors are willing to pay for pipelines increases.

The typical cycle starts with large-cap biotechs with multiple drugs on the market. As investors seek more risk, they invest in companies with a single drug and then move on to development-stage companies. Finally the most-risky investments are new companies going public.

A few years ago, private biotechs couldn't find enough buyers to support initial public offerings. Now IPOs are so oversubscribed that companies such as Dicerna Pharmaceuticals (DRNA) tripled after its IPO this week. Dicerna Pharmaceuticals has a nice drug-discovery unit, but its pipeline is extremely early stage. It's going to be years before investors see any revenue from Dicerna's drugs.

Now, there's nothing more risky in the public biotech sector for investors to move into. The only way for valuations to increase further is for more generalist investors to move into the sector.

Biotechs get snatched up
Another reason biotech valuations remain high is that pharmas and large biotech companies keep snatching them up for premiums. While investing in the hopes of a takeout is generally a pretty poor investment thesis, it's certainly on investors' minds and adds something to the valuation of many biotechs.

Just the rumor of a buyout is enough to send a stock soaring. Ariad Pharmaceuticals (NASDAQ: ARIA) spiked 20% in one day last week when the London Mail newspaper said Eli LillyGlaxoSmithKline and Shire are all potentially interested in buying the company.

It doesn't really matter whether Ariad Pharmaceuticals gets bought. The industry can handle rumors that don't turn out to be true.

What's important is that some biotechs get purchased this year, giving everyone else hope that the companies they own might get bought too.

Good old-fashioned earnings
The Nasdaq Biotechnology Index is made up of 116 stocks, but the top six make up around 40% of the index.

The value of those large biotechs -- Regeneron Pharmaceuticals (REGN 2.12%) and Amgen (AMGN 1.56%) have the largest weight as of the last update -- is driven less by their pipeline than by sales of existing drugs and the earnings they create. Even if investors pull back on their risk tolerance, the value of Regeneron, Amgen, and the rest of the larger biotechs won't change all that much as long as their earnings are growing at a reasonable rate.

Be careful out there
I'm not going to call the top, because predicting the end to euphoria is always difficult. But we've been through this before, and when the bubble pops, it isn't going to pretty. Selling begets selling.

For that reason, I think investors are much better off owning a basket of well-selected biotechs that they can sell when the potential reward doesn't justify the risk rather than owning the broader index through an ETF. Owning fewer stocks may be more risky because one failed trial will take a larger chunk out of the biotech portion of your portfolio, but the flexibility makes up for it.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Stock Quote
Amgen
AMGN
$286.40 (1.56%) $4.41
Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
REGN
$751.70 (2.12%) $15.62
Dicerna Pharmaceuticals Stock Quote
Dicerna Pharmaceuticals
DRNA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.